| Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients SK Hegazy, S Tharwat, AH Hassan Journal of Clinical Virology Plus 3 (2), 100151, 2023 | 11 | 2023 |
| Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients SK Hegazy, S Tharwat, AH Hassan World Journal of Clinical Cases 11 (26), 6105, 2023 | 5 | 2023 |
| Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients SK Hegazy, S Tharwat, AH Hassan Open Medicine 18 (1), 20230768, 2023 | 5 | 2023 |
| Atorvastatin for reduction of 28-day mortality in severe and critical COVID-19 patients: a randomized controlled trial NH Eltahan, NH Elsawy, KM Abdelaaty, AS Elhamaky, AH Hassan, ... Respiratory Research 25 (1), 97, 2024 | 2 | 2024 |
| Comparing the Efficacy of Remdesivir, Favipiravir, and Casirivimab and Imdevimab on Duration of Hospitalization and ICU Stay of Hospitalized COVID-19 Patients SK Hegazy, AH Hassan Life science research communications 1 (1), 2024 | 1 | 2024 |
| Clinical Study to Evaluate the Possible Efficacy and Safety of Antibodies Combination (casirivimab and imdevimab) versus standard antiviral therapy as antiviral agent against … AH Hassan, SK Hegazy, ST Radwan medRxiv, 2022.08. 20.22279020, 2022 | 1 | 2022 |
| The effect of combination treatment with casirivimab and imdevimab versus standard antiviral therapy on clinical outcomes in hospitalized COVID-19 patients SK Hegazy, AH Hassan Discover Medicine 1 (1), 71, 2024 | | 2024 |
| Clinical study to evaluate the possible efficacy and safety of antibodies combination (casirivimab and imdevimab) versus standard antiviral therapy as antiviral agent against … AH Hassan, SK Hegazy, ST Radwan Research Square, 10.21203/rs.3.rs-1991618/v2, 2023 | | 2023 |
| Study to compare the Possible Efficacy and Safety of casirivimab and imdevimab combination versus standard antiviral therapy in hospitalized COVID-19 patients AHH Sahar K.Hegazy Research Square, 10.21203/rs.3.rs-1991618/v1, 2022 | | 2022 |
Sahar Kamal HegaziClinical Pharmacy Department, Faculty of Pharmacy, Tanta University, EGYPTVerified email at pharm.tanta.edu.eg
